Sulfinpyrazone
Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.
![]() | |
| Clinical data | |
|---|---|
| Trade names | Apo-sulfinpyrazone |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682339 |
| Routes of administration | oral intravenous |
| ATC code |
|
| Pharmacokinetic data | |
| Protein binding | 98–99% |
| Metabolism | hepatic |
| Excretion | renal |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.325 |
| Chemical and physical data | |
| Formula | C23H20N2O3S |
| Molar mass | 404.48 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.
Contraindications
Sulfinpyrazone must not be used in persons with renal impairment or a history of uric acid kidney stones.[1]
References
- Underwood M (June 2006). "Diagnosis and management of gout". BMJ. 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078. PMID 16740561.
